Mersana Therapeutics Receives $33,000,000 Series C Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=83d86111-25c5-4221-8c34-704bdb0f14fe - Date
6/16/2016 - Company Name
Mersana Therapeutics - Mailing Address
840 Memorial Drive Cambridge, MA 02139 USA - Company Description
Mersana Therapeutics, Inc. (formerly Nanopharma Corp.) is focused on developing novel oncology agents based on Fleximer, a stealth material that enhances the pharmacokinetics and safety of drugs. - Website
http://www.mersana.com - Transaction Type
Venture Equity - Transaction Amount
$33,000,000 - Transaction Round
Series C - Proceeds Purposes
Mersana plans to use the proceeds to further develop its pipeline programs and expand its proprietary ADC platform. The Company currently anticipates filing an Investigational New Drug (IND) application for lead candidate XMT-1522, a novel HER-2 targeting therapy, in mid-2016, and plans to initiate a Phase 1 proof of concept clinical trial shortly thereafter. Mersana’s second program, XMT-1536, a novel anti-sodium-dependent phosphate transport protein 2B (anti-NaPi2b) ADC, is currently advancing into IND-enabling studies. - M&A Terms
- Venture Investor
Wellington Management Company - Venture Investor
Cormorant Asset Management - Venture Investor
Arrowpoint Partners - Venture Investor
Takeda Ventures - Venture Investor
New Enterprise Associates - Venture Investor
Rock Springs Capital
